Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 6/20 | 0.66 |
| ▸ | RBPJ | Q06330 | 4/20 | 0.66 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.64 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.64 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.64 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.64 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.64 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.64 |
| ▸ | NOTCH3 | Q9UM47 | 2/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.60 |
| ▸ | CCKBR | P32239 | 4/20 | 0.60 |
| ▸ | CCKAR | P32238 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005977 | 0.90 | NOTCH1 (0.72) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL8244069 | 0.88 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL5839093 | 0.88 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3287486 | 0.88 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3287198 | 0.88 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3287317 | 0.88 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3293655 | 0.88 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3287669 | 0.86 | NOTCH1 (0.68) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL13325960 | 0.83 | NOTCH1 (0.47) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3289695 | 0.83 | NOTCH1 (0.74) | NOTCH1RBPJPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718795-B2 | Succinoylamino benzodiazepines as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7507815-B2 | Succinoylamino lactams as inhibitors of a-β protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7456172-B2 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-07-17 | — | — | US | disclosed |
| US-7304055-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304056-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304049-B2 | Succinoylaminobenzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | PSEN1, APP, GABRA6 | NOTCH1 528/4885RBPJ 3834/4885PSEN1 1/4885 |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | GABRA5, APP, GABRE | NOTCH1 942/4885RBPJ 1868/4885PSEN1 15/4885 |
| US-20080293692-A1 | SUCCINOYLAMINO LACTAMS AS INHIBITORS OF A-BETA PROTEIN PRODUCTION | BACE1, APH1A, APP | NOTCH1 94/4885RBPJ 1902/4885PSEN1 7/4885 |
| US-20080207602-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF ABETA PROTEIN PRODUCTION | BACE1, APP, GABRE | NOTCH1 539/4885RBPJ 2293/4885PSEN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.